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Abstract
Background: Blood transfusions are often used as a potential treatment for cancer-related fatigue in anaemic
palliative care patients. However, evidence of benefit using validated outcomes measures is lacking.
Aim: The aim of this study was to test the feasibility of using two such tools; the Brief Fatigue Inventory and
FACT F-fatigue subscale, to measure change in fatigue following a blood transfusion.
Method: Anemic cancer patients receiving specialist palliative care and undergoing transfusion for fatigue,
completed the tools pre- and 3 days post-transfusion.
Results: Thirty patients with cancer-related fatigue who received a blood transfusion completed the study. Both
measures were capable of detecting statistical and clinically significant change in fatigue following transfusion.
Furthermore, the measures showed significant differences between patients that did, or did not, report an overall
improvement in fatigue. Patients found the measures easy to complete with no preference for one over another.
Future clinical trials of blood transfusion for the management of fatigue should incorporate these validated
outcome measures.
Introduction
Cancer-related fatigue has been defined as a distres-sing, persistent, subjective sense of tiredness or exhaus-
tion related to cancer or cancer treatment that is not
proportional to recent activity and interferes with usual
functioning.1 It has been reported as one of the most common
cancer-related symptoms, with a prevalence of 32%–90%.2,3
Fatigue has a significant impact on quality of life (QOL); 61%
of patients with cancer reported that it affected their lives
more than cancer-related pain and 19%were so debilitated by
fatigue that they felt an urge to die.4 Despite the scale and
depth of this symptom it remains under recognised and under
treated in patients with cancer.1 This may reflect a failure to
acknowledge its profound impact on QOL, a general accep-
tance of the inevitability of fatigue and a perceived paucity of
treatment options.
The cause of cancer-related fatigue is multifactorial and not
clearly understood. Various studies have shown an association
between fatigue and biochemical, physical and psychological
factors.5–7 The management of cancer-related fatigue involves
correction of reversible causes, including anaemia, the use of
pharmacologic agents, principally steroids and central nervous
system stimulants, lifestyle modification, and exercise.
In practice, since anemia can be identified in approximately
70% of hospice inpatients, the question of whether it is sig-
nificantly contributing to the symptom of fatigue and there-
fore should be treated is one commonly encountered by
physicians.8 Blood transfusion remains the mainstay of
treatment for anemia- associated fatigue, and 6%–13% of
hospice inpatients are transfused.9,10 Although there is no
absolute level of hemoglobin to trigger transfusion, mean
pretransfusion hemoglobin is usually approximately 8 g/dL
with most patients receiving a single transfusion of 2–3 units
of blood.9,11,12 The mean number of days between transfusion
and death ranges from 47 to 117 days.9,10,12,13
In a study of 91 palliative care patients, shortness of breath,
well-being, and strength improved significantly 2 days post-
transfusion with improvements in well-being and strength
sustained over 2 weeks. In this study 76% of patients felt
better for the transfusion after 2 days and 72% at 2 weeks.11 In
a separate study of 31 patients receiving a blood transfusion
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after admission to a specialist palliative care unit, 51% re-
ported an improvement in well-being the day after transfu-
sion.10 A more recent study of 61 transfused palliative care
patients reported a significant improvement in shortness of
breath, well-being, and fatigue the day after transfusion.
However, only in well-being was this improvement sustained
at 2 weeks.13 In these studies fatigue was either not specifi-
cally measured or not measured using a validated fatigue
assessment tool.
A number of tools have been developed and validated for
the assessment of fatigue in cancer patients. These include the
Functional Assessment of Cancer Therapy–Fatigue subscale
(FACT F–Fatigue Subscale) and the Brief Fatigue Inventory
(BFI).14,15 Both tools are short yet retain strong psychometric
properties.16
This multicenter, prospective study was designed to eval-
uate the feasibility of using these two tools to assess the effi-
cacy of blood transfusion in cancer-related fatigue treatment
in a future large open label study exploring predictors of re-
sponse to transfusion.
Methods
The study received ethical approval from Leeds East Re-
search Ethics Committee (REC reference no. 07/H1306/96)
and all patients provided written informed consent.
Patients were recruited from four specialist palliative care
units over a 17-month period, between 2007 and 2009. Pa-
tients were invited to participate if they were receiving spe-
cialist palliative care from one of the units, either as an
inpatient or via day therapy, and a blood transfusion was
planned to manage their fatigue in keeping with local unit
practice. Inclusion criteria were: more than 18 years of age, a
cancer diagnosis, able to provide written informed consent,
and judged by their clinician to have the mental capacity to
participate in the study. Recruitment was continued until 30
patients had analyzable data, in keeping with guidance on
pilot study design.17
Fatigue was measured using the FACT F-Fatigue Subscale
and BFI questionnaires. The FACT-Anemia was designed to
measure QOL and anemia-related symptoms in patients with
cancer using a 55-item questionnaire.15 The 13-item fatigue
subscale of this questionnaire has been shown to have good
internal reliability (a¼ 0.93, 0.95), has been used to predict
hemoglobin levels and to assess response to fatigue treat-
ment.15,18 Each item ismeasured on a 5-point Likert scale with
a total possible score of 0–52, where higher scores denote
lower levels of fatigue. An improvement or deterioration in
score of 3 or more points indicates a minimal clinically im-
portant difference.19
The BFI was developed and validated internationally for
the assessment of fatigue in patients with cancer.14 It has good
internal reliability (a¼ 0.96) and has been used to assess re-
sponse to fatigue treatment.14,20 The 9-item questionnaire
rates fatigue severity (now, usual andworst) and its impact on
function using 0–10 numerical rating scales where higher
scores denote higher levels of fatigue. The mean of the total
score is calculated as the global fatigue score (0–10). Severe
fatigue, with the greatest impact on function, is indicated by a
worst fatigue level of 7 or more.14
We measured fatigue using the two scales in the 24 hours
prior to transfusion and 3 days after the last unit trans-
fused. This time frame was chosen to allow levels of 2,3-
diphosphoglycerate in the transfused erythrocytes to return to
normal. This affects the affinity of hemoglobin for oxygen and
therefore may affect transfusion effectiveness.21 Participants
were asked to state their preference of questionnaire with
regards to ease of completion and relevance to their situation
after completion of the baseline questionnaires. During the
final assessment they were asked to indicate ‘‘yes’’ or ‘‘no’’ to a
simple question enquiring whether they felt the blood trans-
fusion had helped their fatigue.
Data on baseline demographics, cancer type, presence of
metastases, pretransfusion hemoglobin, place of transfusion,
and number of red cell units transfused were collected.
Primary outcome measures were change in FACT F-
Fatigue Subscale and BFI between baseline and 3 days post-
transfusion. Secondary outcome measures were patients’
assessment of the impact of transfusion on fatigue, preference
for fatigue tool, and recruitment rate. We did not check
posttransfusion hemoglobin because this is not normal clini-
cal practice.
Change in paired fatigue scores between baseline and 3
days posttransfusion were compared using Wilcoxon signed-
rank test. Median changes in fatigue scores for patients that
reported an improvement (responders) and thosewho did not
(nonresponders) were compared using the Mann-Whitney U
test. All p values were two-sided and a value of <0.05 was
considered significant. Data were analyzed using SPSS 16.0
software (SPSS Inc., Chicago, IL).
Results
Of the 58 patients approached, 48 commenced the study
with 32 completing. Data for analysis were obtained from 30
patients (1 patient did notmeet the inclusion criteria and 1 had
datamissing). Of thosewho commenced the study but did not
complete it, 13 of 48 dropped out between the first and second
set of questionnaires, whichwas due to deteriorating health or
death in 8 of 48 and 1 of 48 due to finding the questionnaires
too arduous.
The mean age was 68 (range, 53–91) and 19 of 30 patients
were male The site of the underlying primary cancer was
as follows: gastrointestinal tract, 14; prostate, 7; respiratory
system, 2; breast, 2; hematological, 2; gynecological, 2; renal–
urinary tract, 2; other, 1; and 24 of 30 had metastatic disease.
Baseline median fatigue scores were 12.5 (1.00–47.67) on the
FACT F-Fatigue Subscale (0–52), 7.72 (1.89–10.0) on the BFI
global fatigue score (0–10) and 9.0 (3.0–10.0) on worst fatigue
on BFI (0–10).
The majority of transfusions (28/30) occurred on an inpa-
tient basis. The mean pre transfusion hemoglobin level was
7.96 g/dL (5.3–10.7 g/dL). The mean number of units trans-
fusedwas 2.53 (range, 1–5)with 18 of 30 of patients receiving 2
units. Transfusion episodes occurred over a mean of 1.6 days
(range 1–4).
There was a statistically significant improvement in fatigue
as measured by both fatigue tools between baseline and 3
days posttransfusion (Table 1). Compared to baseline the
median change in score improved by 5 points ( p< 0.001) on
the FACT F-fatigue subscale, and by 1.01 points ( p< 0.05) on
the BFI. In terms of the proportion of patients experiencing a
minimal clinically important difference, 21 of 30 patients re-
ported an improvement in FACT F-Fatigue Subscale of 3 or
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more points. The number of patients reporting severe fatigue
on the worst fatigue domain of the BFI (score of 7 or more) fell
from 27 of 30 patients at baseline to 15 patients following
transfusion.
Following transfusion 22 patients reported that it had
helped their fatigue, 3 were unsure, and 5 reported no
noticeable improvement. Nonresponders were classed as
thosewhowere unsure and thosewho noted no improvement
following transfusion. No significant difference was found
between these two groups at baseline in either fatigue score or
other characteristics. After transfusion there was a statistically
significant difference in fatigue scores between these groups,
with responders showing an improvement in fatigue (Table
2). Of the 21 patients who achieved at least a minimal clini-
cally important difference using the FACT F-Fatigue Subscale,
18 classified themselves as responders, and 3 did not.
Regarding ease of use, 12 patients preferred the FACT
F–Fatigue Subscale, 9 the BFI and 9 expressed no preference.
Regarding relevance of the questionnaire, 12 patients had no
preference, 10 preferred the FACT F–Fatigue Subscale and 7
the BFI, none of which reached statistical significance.
Discussion
Both the FACT F-Fatigue Subscale and BFI were able to
detect statistically significant changes in fatigue after a blood
transfusion. They also appear to reflect the patient experience
of improvement in fatigue. After transfusion, changes in the
scores of 21 patients suggested that this statistically significant
change was clinically meaningful also.
This study adds to the findings of previous studies showing
an improvement in well-being and strength after blood
transfusion by specifically measuring fatigue using validated
fatigue tools. Patient response has previously been elicited by
asking patients whether they felt better 1–2 days after trans-
fusion or whether their well beingwas improved the day after
transfusion. We specifically asked whether the blood trans-
fusion had helped fatigue as it is likely that semantics are
important here. Weakness, strength, and well-being may not
be equivalent to fatigue and this justifies the need to use
validated assessment tools.
Despite the development of other treatment options such as
psychostimulants,22 the clinical issue remains that the majority
of specialist palliative care patients are both anemic and suf-
fering from fatigue and that blood transfusion is understand-
ably considered an option for management. However, this
treatment option is one that is a valuable resource, invasive to
the patient, and not without risk. To complicate decision mak-
ing further, it is difficult to determine the chance of benefit from
transfusion in this setting using clinical data. For example, two
studies in palliative care patients found no significant correla-
tion between haemoglobin level and fatigue.23,24 Similar studies
in this context have also found that pretransfusion hemoglobin
level does not correlate with response to transfusion.10,11 We
were also unable to detect in our study any pretransfusion
differences in patients that subsequently did, or did not, re-
spond based on self-ratings. These findings contrast with
studies in patientswith cancerwithout advanced diseasewhere
hemoglobin level is more closely correlated to fatigue and
clinical response to hemopoetic growth factors.25 This high-
lights the multifactorial nature of fatigue in advanced disease.
We did not set out to test the effectiveness of blood trans-
fusion for fatigue and so our findings of benefit should be
regarded with caution. Our study was not blinded or placebo
controlled and there may be a strong placebo response to
receiving a blood transfusion. Most transfusions occurred on
an inpatient basis and the act of admission to a specialist
palliative care unit may in itself aid fatigue as might im-
provements in control of other symptoms. We did not control
for changes in baseline medications, including potential
Table 1. Median Fatigue Scores
Fatigue tool Pretransfusion (range) Posttransfusion (range) Median change (range)
FACT F-Fatigue Subscale 12.5 (1.0–47.67) 23.50 (0.0–52.0) 5.00a (9–37)
BFI GFS 7.72 (1.89–10.0) 5.44 (0.56–8.88) 1.01b (9.44–4.22)
BFI worst 9.0 (3.0–10.0) 6.50 (0–10) 1.50a (10–4)
ap 0.001.
bp 0.05.
FACT F-Fatigue Subscale, Functional Assessment for Cancer Therapy Fatigue Subscale; BFI GFS, Brief Fatigue Inventory Global Fatigue
Score; BFI worst, Brief Fatigue Inventory worst fatigue score.
Table 2. Median Fatigue Scores of Responders Compared to Nonresponders
Pretransfusion Posttransfusion Median change
Fatigue tool Response group Score p Score p Score p
FACT F-Fatigue Subscale Nonresponders 9.00 0.111 8.00 0.001 1.00 0.012
Responders 18.00 27.00 9.50
BFI Global Fatigue Score Nonresponders 8.28 0.313 8.06 0.005 0.50 0.041
Responders 7.06 4.83 1.71
Worst fatigue on BFI Nonresponders 8.00 0.071 9.00 0.008 0.00 0.08
Responders 8.00 6.00 2.50
p values calculated between responders and nonresponders.
FACT F-Fatigue Subscale, Functional Assessment for Cancer Therapy Fatigue Subscale; BFI, Brief Fatigue Inventory.
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treatments for fatigue although in our local centers it is good
clinical practice not to start a second treatment while awaiting
the outcome of a first.
In summary, this is the first study to investigate validated
measures of fatigue to assess response to transfusion in patients
within palliative care services. We have demonstrated that
thesemeasures are capable of detecting statistical and clinically
significant change in fatigue following transfusion. Further-
more, the measures showed significant differences between
patients that did, or did not, report an overall improvement in
fatigue. Patients found the measures easy to complete with no
preference for one over another. Future clinical trials of blood
transfusion for themanagement of fatigue should incorporate a
validated outcomemeasures such as FACT F–Fatigue Subscale
or BFI. Although these data support a potential effect of blood
transfusion on quality of life for some patients, there remains a
need to determine predictors of response to blood transfusion
before we can state this with certainty.
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